Show simple item record

dc.creatorAllegri, Ricardo Francisco
dc.description.abstractNeurodegenerative dementias have been described based on their phenotype, in relation to selective degeneration occurring in a particular neuroanatomical system. More recently however, the term proteinopathy has been introduced to describe diseases in which one or more altered proteins can be detected. Neurodegenerative diseases can be produced by more than one abnormal protein and each proteinopathy can determine different clinical phenotypes. Specific biomarkers have now been linked to certain molecular pathologies in live patients. In 2016, a new biomarker-based classification, currently only approved for research in Alzheimer’s disease, was introduced. It is based on the evaluation three biomarkers: amyloid (A) detected on amyloid-PET or amyloid- beta 42 assay in CSF; tau (T) measured in CSF as phosphorylated tau or on tau PET imaging; and neuronal injury/neurodegeneration (N), detected by total T-tau in CSF, FDG PET hypometabolism and on MRI brain scan. Results of clinical research using the ATN biomarkers at FLENI, a Neurological Institute in Buenos Aires, Argentina have, since 2011, contributed to ongoing efforts to move away from the concept of neurodegenerative dementias and more towards one of cognitive proteinopathies. Today, clinical diagnosis in dementia can only tell us “where” abnormal tissue is found but not “what” molecular mechanisms are involvedspa
dc.publisherCorporación Universidad de la Costaspa
dc.rightsCC0 1.0 Universal*
dc.sourceDementia e Neuropsychologiaspa
dc.subjectAlzheimer diseasespa
dc.subjectFrontotemporal dementiaspa
dc.titleMoving from neurodegenerative dementias, to cognitive proteinopathies, replacing “where” by “what”spa
dcterms.references1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804. 10.1056/NEJMoa1202753spa
dcterms.references2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939-44.
dcterms.references3. Mendez PC, Surace E, Bérgamo Y, Calandri I, Vázquez S, Sevlever G, et al. Biomarkers for Alzheimer's disease. Where we stand and where we are headed. Medicina (B Aires). 2019;79(Spec 6/1)
dcterms.references4. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-29.
dcterms.references5. Allegri RF, Vazquez S, Sevlever G. Enfermedad de Alzheimer: Nuevos Paradigmas. Buenos Aires: Editorial Polemos;
dcterms.references6. Cairns NJ, Perrin RJ, Franklin EE, Carter D, Vincent B, Xie M, et al. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology. 2015;35(4):390-400.
dcterms.references7. Pievani M, Filippini N, van den Heuvel MP, Cappa SF, Frisoni GB. Brain connectivity in neurodegenerative diseases--from phenotype to protein pathy. Nat Rev Neurol. 2014;10(11):620-33.
dcterms.references8. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503-27.
dcterms.references9. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-14.
dcterms.references10. Takeda S. Progress ion of Alzheimer's disease, tau propagation, and its modifiable risk factors. Neurosci Res. 2019;141:36-42.
dcterms.references11. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-46.
dcterms.references12. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging - Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257-62.
dcterms.references13. Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-47.
dcterms.references14. Russo MJ, Gustafson S, Vázquez S, Surace E, Guinjoan S, Allegri RF, et al. Creation of the Argentina - Alzheimer Disease Neuroimaging Initiative. Alzheimers Dementia. 2014;10(1 Suppl):S84-7.
dcterms.references15. Carrillo MC, Bain LJ, Frisoni GB, Weiner MW. Worldwide Alzheimer’s disease neuroimaging initiative. Alzheimers Dement. 2012;8(4):337-42.
dcterms.references16. Weiner MW, Aisen PS, Jack Jr CR, Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer’s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010;6(3):202-11.
dcterms.references17. Surace E, Cohen G, Chrem Méndez P, Martin ME, Smyth E, Russo G, et al. Latin American Experience with Alzheimer’s disease. Cerebrospinal Fluid Biomarkers. J Am Geriatr Soc. 2013;61(7):1229-31.
dcterms.references18. Harris P, Fernández Suarez M, Surace EI, Chrem Méndez P, Martín ME, Clarens MF, et al. Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina - Alzheimer’s Disease Neuroimaging Initiative). Neuropsychiatr Dis Treat. 2015;11:2599-604. 10.2147/NDT.S84292spa
dcterms.references19. Chrem P, Cohen G, Russo MJ, Fernandez M, Nahas F, Russo G, et al. Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic. Am J Alzheimers Dis Other Demen. 2015;30(6):599-606.
dcterms.references20. Russo MJ, Cohen G, Chrem Mendez P, Campos J, Nahas FE, Surace EI, et al. Predicting episodic memory performance using different biomarkers: results from Argentina-Alzheimer's Disease Neuroimaging Initiative. Neuropsychiatr Dis Treat. 2016;12:2199-206.
dcterms.references21. Russo MJ, Campos J, Vázquez S, Sevlever G, Allegri RF. Alzheimer's disease neuroimaging initiative. Adding recognition discriminability index to the delayed recall is useful to predict conversion from mild cognitive impairment to Alzheimer's disease in the Alzheimer's disease neuroimaging initiative. Front Aging Neurosci. 2017;9:46.
dcterms.references22. Russo MJ, Cohen G, Campos J, Martin ME, Clarens MF, Sabe L, et al. Usefulness of discriminability and response bias indices for the evaluation of recognition memory in mild cognitive impairment and Alzheimer disease. Dement Geriatr Cogn Disord. 2017;43(1-2):1-14.
dcterms.references23. Méndez PC, Calandri I, Nahas F, Russo MJ, Demey I, Martín Meet, et al. Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI): neuropsychological evolution profile after one-year follow up. Arq Neuropsiquiatr. 2018;76(4):231-40.
dcterms.references24. Russo MJ, Cohen G, Méndez PC, Campos J, Martín ME, Clarens MF, et al. Utility of the Spanish version of the Everyday Cognition scale in the diagnosis of mild cognitive impairment and mild dementia in an older cohort from the Argentina-ADNI. Aging Clin Exp Res. 2018;30(10):1167-76.
dcterms.references25. Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62.
dcterms.references26. Allegri RF, Chrem Mendez P, Calandri I, Cohen G, Martin ME, Russo MJ, et al. Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine-Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dementia (Amst). 2020;12(1):e12026.
dcterms.references27. Niikado M, Méndez PC, Itzcovich T, Barbieri-Kennedy M, Calandri I, Martinetto H, et al. Evaluation of cerebrospinal fluid neurofilament light chain as a routine biomarker in a memory clinic. J Gerontol A Biol Sci Med Sci. 2019;74(4):442-5.
dcterms.references28. Riudavets MA, Bartoloni L, Troncoso JC, Pletnikova O, St George-Hyslop P, Schultz M et al. Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation. Brain Pathol. 2013;23(5):595-600.
dcterms.references29. Itzcovich T, Méndez PC, Vázquez S, Barbieri-Kennedy M, Niikado M, Martinetto H, et al. A novel mutation in PSEN1 (p.T119I) in an Argentine family with early- and late-onset Alzheimer's disease. Neurobiol Aging. 2020;85:155.e9-155.e12.

Files in this item


This item appears in the following Collection(s)

Show simple item record

CC0 1.0 Universal
Except where otherwise noted, this item's license is described as CC0 1.0 Universal